Kinsey RD, Archambault GF, Foster TAPharmacy in the US Public Health Service: then and now. J Am Pharm Assoc.1948 ;9:345-347, 376, 378, 380, 383-384.
2.
The CommissionedCorps of the United States Public Health Service: Health Leadership in a Time of Change. Washington, DC: Commissioned Officers Association of the United States Public Health Service; March, 1993.
3.
Moore SR, Abramek FJThe US Public Health Service Commissioned Corps pharmacist: the evolution of professional practice. Pharmacy in History.1992;34:110-115.
4.
Furman B.A Profile of the United States Public Health Service 1798-1948. Washington, DC: Dept of Health, Education, and Welfare;1973. Publication 73-369.
5.
Paavola FG, Dermanoski K., Pittman R.Pharmaceutical services in the United States Public Health Service. Am J Health Syst Pharm.1997;54:766-772.
6.
Zimmerman PF , Larsen RK, Barkley EW, Gallelli JFRecommendations for the safe handling of injectable antineoplastic drug products. Am J Hosp Pharm.1981;38:1693-1695.
7.
Vaccari PL, Tonat K., DeChristoforo R., Gallelli JF, Zimmerman PFDisposal of antineoplastic wastes at the National Institutes of Health. Am J Hosp Pharm.1984;41:87-93.
8.
US Dept of Health and Human Services, Public Health Service, Washington, DC: National Institutes of Health; 1992. NIH Publication 92-2621.
9.
Kohler DR, Montello MJ, Green L., Huntley C., High JL, Fallavollita A., Goldspiel BRStandardizing the expression and nomenclature of can- cer treatment regimens . Am J Health Syst Pharm.1998; 55:137-144.
10.
DeCederfelt HJ , Grimes GJ, Green L., DeCederfelt RO, Daniels CEHandling of gene-transfer products by the National Institutes of Health Clinical Center pharmacy department. Am J Health Syst Pharm.1997; 54:1604-1610.
11.
Montello MJ , Greenblatt JJ, Fallavollita A., Shoemaker D.Accessing investigational anticancer agents outside of clinical trials. Am J Health Syst Pharm.1998;55:651-652, 660.
12.
McIntosh H.25 years ahead: will cancer be a "background-noise kind of disease"? J Natl Cancer Inst.1996 ; 88:1794-1798.
